YOLFTbeta
Zura Bio Limited Class A Ordinary Shares

Zura Bio Limited Class A Ordinary Shares

ZURA · NASDAQ · Healthcare / Biotechnology

1.24USD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close1.24
Open1.24
Day Range1.13 – 1.25
52-Week Range3.15 – 7.44
Volume4.24M
Market Cap398.65M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.12
Dividend Yield0.00%
Beta-0.03
50-Day Avg5.39
200-Day Avg5.32

About

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Sandeep Chidambar Kulkarni M.D.
  • Employees40
  • Headquarters1489 W. Warm Springs Road, Henderson, NV, United States, 89014, USA
  • Websitehttps://zurabio.com

Leadership

  • Dr. Sandeep Chidambar Kulkarni M.D.Co-Founder, CEO & Director · b. 1981
  • Ms. Kimberly Ann Davis J.D.COO, Chief Legal Officer & Corporate Secretary · b. 1968
  • Dr. Kiran Nistala MBBS, Ph.D.Chief Medical Officer & Head of Development · b. 1973
  • Ms. Marlyn MathewVP of Finance & Accounting and Principal Financial & Accounting Officer · b. 1984
  • Dr. Gary Whale Ph.D.Chief Technology Officer · b. 1974
  • Ms. Theresa LowryChief Human Resources Officer · b. 1974
  • Mr. Muzammil MustufaChief Business Officer

Financials

Income Statement

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-0000
Cost of Revenue---9.00K49.00K
Gross Profit----9.00K-49.00K
Operating Expense---55.18M75.20M
Operating Income-1.09M-27.16M-62.64M-55.19M-75.25M
EBITDA8.42M-27.33M-60.56M-52.39M-68.60M
Net Income8.42M-25.74M-60.36M-52.40M-68.65M
R&D-23.69M44.00M24.40M42.08M

Balance Sheet

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets140.55M5.26M100.84M179.53M113.95M
Total Liabilities10.35M27.32M21.29M19.51M12.41M
Total Equity130.20M-32.06M59.33M146.81M101.54M
Cash729.22K1.57M99.81M176.50M109.41M
Total Debt-7.76M---
Net Debt-729.22K6.19M-99.81M-176.50M-109.41M

Cash Flow

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.10M-1.20M-15.05M-28.08M-64.81M
Investing Cash Flow-139.38M-12.00M-8.00M-5.08M-113.00K
Financing Cash Flow141.21M14.77M121.29M109.84M-2.16M
Capital Expenditure412.00M8.00M75.00K113.00K
Free Cash Flow-1.10M-13.20M-23.05M-28.15M-64.93M
FCF to OCF100.00%1098.34%153.14%100.27%100.17%

Earnings

Report DateAug 27, 2021Nov 19, 2021Dec 31, 2021Apr 11, 2022Aug 12, 2022Nov 14, 2022Mar 28, 2023May 31, 2023Aug 14, 2023Nov 13, 2023Mar 28, 2024May 9, 2024Aug 13, 2024Nov 7, 2024Mar 25, 2025May 8, 2025Aug 14, 2025Nov 13, 2025Mar 20, 2026May 7, 2026Aug 11, 2026Nov 12, 2026
EPS Estimate0.00-----0.00--0.25-0.23-0.23-0.24-0.15-0.13-0.24-0.16-0.18-0.18-0.15-0.18-0.20-0.22
EPS Actual0.000.350.050.050.130.030.04-2.76-1.31-0.18-0.19-0.02-0.17-0.26-0.10-0.19-0.17-0.21-0.49-0.22-0.21-
Surprise---------424.00%21.74%17.39%91.67%-13.33%-100.00%58.33%-18.75%5.56%-16.67%-226.67%-22.22%-5.00%-
Timing--------Pre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap398.65M
Enterprise Value208.85M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book2.10
EPS-1.12
Book Value2.07
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-92.69M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-51.01%
Return on Assets-31.23%
Shares Outstanding95.83M
Shares Float50.71M
Beta-0.03
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 7 analystsTarget 18.00
  • Strong Buy
    5
  • Buy
    1
  • Hold
    1

Ownership Breakdown

Institutions
87.86%
Insiders
18.92%
Retail / Other
0.00%

Top Institutional Holders

  • Suvretta Capital Management, LLC
    9.07M9.46%
  • VR Adviser, LLC
    6.43M6.72%
  • MPM Oncology Impact Management LP
    4.47M4.67%
  • JPMorgan Chase & Co
    4.46M4.65%
  • Great Point Partners LLC
    4.22M4.40%
  • BRAIDWELL LP
    3.99M4.16%
  • Siren, L.L.C.
    3.73M3.90%
  • COMMODORE CAPITAL LP
    3.25M3.39%
  • Pfizer Inc
    2.84M2.96%
  • Adage Capital Partners Gp LLC
    2.75M2.87%
  • Saturn V Capital Management LLC
    2.10M2.19%
  • Qvt Financial LP
    1.90M1.98%
  • StemPoint Capital LP
    1.51M1.57%
  • Armistice Capital, LLC
    1.51M1.57%
  • Affinity Asset Advisors, LLC
    1.46M1.53%
  • Cormorant Asset Management, LLC
    1.45M1.51%
  • Ikarian Capital, LLC
    1.19M1.25%
  • EcoR1 Capital, LLC
    1.18M1.23%
  • Boxer Capital Management, LLC
    900.00K0.94%

Top Fund Holders

  • iShares Russell 2000 ETF
    1.44M1.50%